The Fort Worth Press - Drew Weissman, Nobel-winning mRNA pioneer

USD -
AED 3.672503
AFN 64.000378
ALL 81.719319
AMD 368.120328
ANG 1.790403
AOA 913.115986
ARS 1429.260602
AUD 1.41299
AWG 1.801525
AZN 1.697505
BAM 1.684662
BBD 2.014307
BDT 122.763646
BGN 1.69088
BHD 0.377198
BIF 2989.857226
BMD 1
BND 1.282253
BOB 6.910839
BRL 5.078301
BSD 1.000134
BTN 94.672782
BWP 13.41861
BYN 2.768827
BYR 19600
BZD 2.011413
CAD 1.39823
CDF 2295.000232
CHF 0.793599
CLF 0.022681
CLP 892.650219
CNY 6.7715
CNH 6.759475
COP 3492.51
CRC 454.982019
CUC 1
CUP 26.5
CVE 94.978251
CZK 20.818983
DJF 177.719854
DKK 6.44282
DOP 58.780714
DZD 133.064977
EGP 50.349403
ERN 15
ETB 161.237628
EUR 0.86196
FJD 2.237202
FKP 0.746148
GBP 0.74475
GEL 2.655019
GGP 0.746148
GHS 11.101445
GIP 0.746148
GMD 73.000119
GNF 8761.079479
GTQ 7.62406
GYD 209.236521
HKD 7.83485
HNL 26.744076
HRK 6.494499
HTG 130.714732
HUF 301.863003
IDR 17704
ILS 2.902595
IMP 0.746148
INR 94.572302
IQD 1310.156512
IRR 1375877.497294
ISK 124.460444
JEP 0.746148
JMD 158.526028
JOD 0.708973
JPY 160.269503
KES 129.398158
KGS 87.450511
KHR 4019.208821
KMF 426.000074
KPW 900.00035
KRW 1514.220217
KWD 0.30815
KYD 0.833473
KZT 489.555787
LAK 22021.999604
LBP 89562.850473
LKR 332.536555
LRD 182.018649
LSL 16.177014
LTL 2.95274
LVL 0.60489
LYD 6.359584
MAD 9.24575
MDL 17.396473
MGA 4155.30719
MKD 53.139347
MMK 2099.090156
MNT 3576.689019
MOP 8.070461
MRU 39.92506
MUR 47.119898
MVR 15.459816
MWK 1734.220557
MXN 17.20605
MYR 4.050304
MZN 63.900812
NAD 16.176944
NGN 1358.26011
NIO 36.806698
NOK 9.534545
NPR 151.476624
NZD 1.71552
OMR 0.384502
PAB 1.00006
PEN 3.401239
PGK 4.380015
PHP 60.294503
PKR 278.247736
PLN 3.66395
PYG 6123.407023
QAR 3.646058
RON 4.512497
RSD 101.176013
RUB 72.451568
RWF 1469.173289
SAR 3.752094
SBD 8.045573
SCR 13.696826
SDG 600.499
SEK 9.384235
SGD 1.282575
SHP 0.746601
SLE 24.649833
SLL 20969.503664
SOS 571.527015
SRD 37.518031
STD 20697.981008
STN 21.103498
SVC 8.750743
SYP 110.532098
SZL 16.174171
THB 32.55404
TJS 9.270929
TMT 3.51
TND 2.926901
TOP 2.40776
TRY 46.281703
TTD 6.788552
TWD 31.536701
TZS 2629.998015
UAH 44.83735
UGX 3715.140944
UYU 40.562483
UZS 11980.705457
VES 581.95784
VND 26290
VUV 119.50104
WST 2.743493
XAF 565.02961
XAG 0.014272
XAU 0.000231
XCD 2.70255
XCG 1.802434
XDR 0.703376
XOF 565.02961
XPF 102.727985
YER 238.593065
ZAR 16.198399
ZMK 9001.207781
ZMW 17.580733
ZWL 321.999592
  • RIO

    0.5300

    105.88

    +0.5%

  • NGG

    -0.2200

    81.62

    -0.27%

  • BTI

    -1.1550

    61.165

    -1.89%

  • CMSD

    0.1000

    22.36

    +0.45%

  • GSK

    -0.8150

    52.225

    -1.56%

  • RYCEF

    0.4600

    17.5

    +2.63%

  • BCE

    -0.2314

    24.0455

    -0.96%

  • BCC

    0.7000

    71.84

    +0.97%

  • BP

    -1.0850

    41.695

    -2.6%

  • JRI

    0.1035

    12.77

    +0.81%

  • VOD

    -0.4950

    15.035

    -3.29%

  • CMSC

    0.0100

    22.34

    +0.04%

  • RBGPF

    0.0000

    60.72

    0%

  • AZN

    -1.5980

    177.152

    -0.9%

  • RELX

    -0.9350

    32.805

    -2.85%

Drew Weissman, Nobel-winning mRNA pioneer
Drew Weissman, Nobel-winning mRNA pioneer / Photo: © AFP

Drew Weissman, Nobel-winning mRNA pioneer

Drew Weissman's decades of research into mRNA technology paved the way for Covid-19 vaccines, finally earning a Nobel prize for the physician-scientist.

Text size:

The 64-year-old University of Pennsylvania immunologist, who won the Nobel Medicine Prize along with long-time collaborator Katalin Kariko on Monday, is far from done.

His next quests include, among others, developing a vaccine against all future coronaviruses.

"There have been three (coronavirus) pandemics or epidemics in the past 20 years," Weissman told AFP recently, referring to the original SARS virus, MERS and Covid-19.

"You have to assume there's going to be more, and our idea was that we could wait for the next coronavirus epidemic or pandemic, and then spend a year and a half making a vaccine. Or we could make one now."

- Twin breakthroughs-

The world is now aware of the elegance of the mRNA (messenger ribonucleic acid) vaccines, that deliver genetic instructions to cells telling them to recreate the spike protein of the coronavirus, in order to trigger effective antibodies when they encounter the real thing.

But back when Weissman teamed up with Kariko in the 1990s, the research was considered a scientific dead-end, and working with DNA was considered a more promising avenue.

"We started working together in 1998, and that was without much funding and without much in the way of publications," he said.

In 2005, the pair found a way to alter synthetic RNA to stop it from causing a massive inflammatory response found in animal experiments.

"Just before our paper was published, I said 'Our phones are going to ring off the hook,'" he recalls.

"We sat there staring at our phones for five years, and they never rang!"

With a second big breakthrough in 2015, they found a new way to deliver the particles safely and effectively to their target cells, using a fatty coating called "lipid nanoparticles."

Both developments are part of the Pfizer and Moderna Covid-19 vaccines today.

- Helping people -

Weissman grew up in Lexington, Massachusetts.

His father and mother, both since retired, were an engineer and dental hygienist, respectively.

"When I was five years old, I was diagnosed as a type-one diabetic, and back then it was testing urine and taking insulin shots a few times a day," he recalled, and this motivated him to pursue science.

He was educated at Brandeis University and completed an MD-Phd program in immunology at Boston University.

As a young fellow at the National Institutes of Health, he worked for several years in Anthony Fauci's lab on HIV research, before finally arriving at his long-time home Penn.

Weissman was a practicing doctor until a few years ago, and says it brings him great joy that his invention has helped save millions of lives.

"I'm a clinician scientist, my dream since starting college and medical school was to make something that helps people. I think I can say that I've done that. So I am incredibly happy," he said.

Beyond vaccines, mRNA technology is also being heralded for its potential across medicine.

Weissman's team is working on using RNA to develop a single-injection gene therapy to overcome the defect that causes sickle cell anemia, a genetic blood disease that 200,000 babies are born with in Africa every year.

Significant technical challenges remain to ensure the treatment is able to correctly edit genes and is safe, but the researchers are hopeful.

Bone marrow transplant, an expensive treatment with serious risks, is currently the only cure.

M.T.Smith--TFWP